Argent BioPharma Ltd. Updates on SINTEF Collaboration for Chronic Wound Management

Rhea-AI Summary

Argent BioPharma (ASX: RGT, OTCQB: RGTLF) reports progress in its collaboration with SINTEF on enhancing antimicrobial therapies for chronic wounds and oncologic wound care. The company has advanced its proprietary antimicrobial compounds using nano-encapsulation technology to improve drug efficacy and targeted delivery.

Key achievements include establishing standardized in vitro assays, identifying Synthetic Wound Fluid (SWF) as the optimal testing medium, and selecting promising APIs with pH-dependent antimicrobial activity. The research targets diabetic foot ulcers, pressure sores, post-surgical infections, and non-melanoma skin cancer excisions.

The next phase will focus on refining API combinations for nano-encapsulation and conducting Minimum Inhibitory Concentration studies. The initiative aims to address biofilm formation, antibiotic resistance, and chronic infections in a global advanced wound care market projected to exceed $15 billion by 2030.

Positive

• Advanced wound care market projected to reach $15 billion by 2030, indicating significant market opportunity
• Successfully identified promising APIs with pH-dependent antimicrobial activity
• Established standardized testing protocols and optimal testing medium (SWF)

Negative

• Product still in early research phase with no immediate revenue potential
• No clinical trial data or regulatory approvals yet

Advanced wound care market projected to exceed $15 billion globally by 2030

PERTH, Australia , Feb. 12, 2025 /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF) has made significant progress in its collaboration with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care. The project leverages nano-encapsulation technology to improve drug efficacy and targeted delivery.

SINTEF, headquartered in Trondheim, Norway, is an independent research organization founded in 1950 that conducts contract research and development projects.

Key Developments:

• Optimizing Antimicrobial Compounds: The company has advanced its proprietary antimicrobial compounds for nano-encapsulation, improving their targeted drug delivery.
• Key Research Milestones Achieved: Standardized in vitro assays have been established, Synthetic Wound Fluid (SWF) identified as the optimal testing medium, and promising active pharmaceutical ingredients (APIs) with pH-dependent antimicrobial activity selected.
• Addressing Critical Wound Care Needs: The initiative focuses on diabetic foot ulcers, pressure sores, post-surgical infections, and potentially non-melanoma skin cancer (NMSC) excisions, aiming to combat biofilm formation, antibiotic resistance, and chronic infections.

Research Progress:

In the project's first phase, Argent BioPharma identified SWF as the most suitable medium for testing antimicrobial efficacy in chronic wound infections. Multiple APIs were screened, revealing promising candidates whose antimicrobial activity is pH-dependent, informing future formulation strategies.

The next phase will refine API combinations for nano-encapsulation and conduct Minimum Inhibitory Concentration (MIC) studies to evaluate synergistic antimicrobial effects. This research aims to develop solutions for persistent infections, biofilm-related complications, and antibiotic resistance.

Market Potential and Strategic Goals:

With the advanced wound care market projected to exceed $15 billion globally by 2030, Argent BioPharma's nano-medicine-driven approach is positioned to transform wound management. The company aims to improve healing outcomes, reduce antibiotic dependency, and expand into oncologic wound care, particularly for post-surgical wounds in NMSC patients.

Commitment to Innovation

Argent BioPharma remains committed to developing innovative therapeutic solutions for unmet medical needs.

for further information please contact:

Argent BioPharma Roby Zomer CEO & Managing Director +61 8 6555 2950 info@argentbiopharma.com

Argent BioPharma Rowan Harland Company Secretary +61 8 6555 2950 info@argentbiopharma.com

 

View original content:https://www.prnewswire.com/news-releases/argent-biopharma-ltd-updates-on-sintef-collaboration-for-chronic-wound-management-302375044.html

SOURCE Argent BioPharma Ltd.

FAQ

What is the market potential for RGTLF's wound care technology?

The advanced wound care market where RGTLF operates is projected to exceed $15 billion globally by 2030.

What are the key developments in RGTLF's collaboration with SINTEF?

RGTLF has advanced its proprietary antimicrobial compounds for nano-encapsulation, established standardized in vitro assays, identified Synthetic Wound Fluid as optimal testing medium, and selected promising APIs with pH-dependent antimicrobial activity.

What medical conditions does RGTLF's wound care technology target?

The technology targets diabetic foot ulcers, pressure sores, post-surgical infections, and potentially non-melanoma skin cancer excisions.

What is the next phase of RGTLF's wound care research?

The next phase will focus on refining API combinations for nano-encapsulation and conducting Minimum Inhibitory Concentration studies to evaluate synergistic antimicrobial effects.

How does RGTLF's nano-encapsulation technology work in wound care?

The technology improves drug efficacy and targeted delivery of antimicrobial compounds, aiming to combat biofilm formation, antibiotic resistance, and chronic infections.